KarimChamieMD
Urology • Los Angeles, CASurgical Oncology
Associate Professor, Urology, UCLA School of Medicine
Dr. Chamie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UCLA Medical Center
200 Medical Plaza, Suite 140
Los Angeles, CA 90095Phone+1 310-794-2858Fax+1 310-794-2858
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Urologic Surgical Oncology, 2011 - 2012- Ronald Reagan UCLA Medical CenterFellowship, Health Services Research, 2010 - 2011
UCLA School of Public HealthMSHS, Health Services Research, 2009 - 2010
University of California Davis HealthResidency, Urology, 2005 - 2009- University of California Davis HealthResidency, Surgery, 2003 - 2005
Keck School of Medicine of the University of Southern CaliforniaClass of 2003
Certifications & Licensure
CA State Medical License 2004 - 2024- American Board of Urology Urology
Awards, Honors, & Recognition
- Research Career Development Award STOP CANCER Research Foundation
- SEED Grant Phase One Foundation
- SEED Grant HH Lee Surgical Society
Clinical Trials
- Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer Start of enrollment: 2010 Dec 01
- Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Start of enrollment: 2014 Mar 01
- A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT Start of enrollment: 2013 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 149 citationsAn open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasi...Vignesh T. Packiam, Donald L. Lamm, Daniel A. Barocas, Andrew Trainer, Benjamin Fand
Urologic Oncology. 2017-07-26 - 29 citationsA phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancerNicholas M. Donin, Karim Chamie, Andrew T. Lenis, Allan J. Pantuck, Madhu Reddy
Urologic Oncology. 2017-02-01 - 879 citationsBladder Cancer: A ReviewAndrew T. Lenis, Patrick M Lec, Karim Chamie, M D Mshs
JAMA. 2020-11-17
Journal Articles
- Radical Prostatectomy Then and Now: Surgical Overtreatment of Prostate Cancer Is Declining from 2009 to 2016 at a Tertiary Referral CenterAmirali Salmasi, Izak Faiena, Karim Chamie, Urologic Oncology
Press Mentions
FDA Approval of Anktiva Heralds a New Era in the Treatment of BCG-Unresponsive Non–Muscle-Invasive Bladder CancerApril 23rd, 2024- How Bladder Cancer Immunostimulant N-803 May Shake Things UpApril 20th, 2023
- AUA 2022: Late-Breaking Plenary HighlightsJuly 27th, 2022
- Join now to see all
Grant Support
- Health Disparities in Prostate CancerNIH Loan Repayment Program2012–2016
- Quality of Care in Patients with Bladder CancerAmerican Cancer Society2009–2011
- Quality Of Care In Patients With Bladder Cancer.National Cancer Institute2009–2011
Professional Memberships
- Member
- Member
- Member
- Society of Urologic OncologyMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
